KRAS and neoplasm: This molecule has been reported to sensitize tumor cells to several chemotherapeutic treatments, such as melanoma cells to decarbazine and temozolomide (TMZ), breast cancer cells to Dox and colorectal cancer cells to 5-fluoracil [45], glioblastoma patient-derived xenografts to TMZ [46], KRAS-driven pancreatic ductal adenocarcinoma xenografts to gemcitabine [47] and HNSCC cells and xenografts to Cis-Pt [43].